This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Ad GV.EGR.TNF.11D, golnerminogene pradenovec
Description: TNFerade is a second-generation adenovector carrying the transgene encoding for TNF-alpha. TNFerade is designed to optimize spatial and temporal TNF-alpha gene expresssion following ionizing radiation.
GenVec and Asahi
In February 1998, GenVec entered into a non-exclusive license agreement with Asahi Chemical Industry (Asahi) for rights to all gene therapy applications in the United States to its proprietary form of the TNF-alpha gene. In exchange for this license, GenVec paid a $200,000 non-refundable fee to Asahi and has committed to additional payments upon the achievement of specified clinical milestones, as well as product royalties based on net sales of a licensed product.
As of March 2009, GenVec no longer mentions this partnership in their SEC Filings, as such we are assuming that this partnership has been cancelled.
GenVec and Fuso
In December 2002, Genvec announced a new, three-year $4.5 million funded research agreement with Fuso Pharmaceuticals. This follows the successful conclusion of a former collaboration, which ran from 1997 to 2002. Genvec established the new collaboration to identify a targeted cancer therapy product candidate...See full deal structure in Biomedtracker
Partners: Fuso Pharmaceuticals
Pink Sheet FDA puts hold on GenVec TNFerade
Pink Sheet GenVec appoints chief medical officer
Additional information available to subscribers only: